Northland Securities analyst Carl Byrnes maintained a Buy rating on Opiant Pharmaceuticals (OPNT) today and set a price target of $42.00. The company’s shares closed last Thursday at $13.29.
According to TipRanks.com, Byrnes has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -6.2% and a 36.1% success rate. Byrnes covers the Healthcare sector, focusing on stocks such as Aridis Pharmaceuticals, Oncternal Therapeutics, and Adamas Pharmaceuticals.
Currently, the analyst consensus on Opiant Pharmaceuticals is a Moderate Buy with an average price target of $42.00.
See today’s analyst top recommended stocks >>
The company has a one-year high of $14.98 and a one-year low of $6.79. Currently, Opiant Pharmaceuticals has an average volume of 74.33K.
Based on the recent corporate insider activity of 16 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of OPNT in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Opiant Pharmaceuticals, Inc. engages in the development of pharmaceutical solutions for common addictions and related disorders. It focuses on developing treatment to reverse opioid overdoses, treatment for overweight and obese patients with binge eating disorder and treatment for patients with Bulimia Nervosa. Its principal product Naloxone is a medicine which is available through injection can reverse the overdose of prescription and illicit opioids. Opiant Pharmaceuticals was founded on June 21, 2005 and is headquartered in Santa Monica, CA.
